Clinical trial · no report yet · Phase 2
NCT03469284
MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
- NCT03469284 ↗
- Completed
- M.D. Anderson Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Randomized Controlled Trial Comparing 4 Intervention Arms, Including 3 Different Concentrations of Methylene Blue Oral Rinse Combined With Conventional Therapy and Conventional Therapy, in Patients With Intractable Pain Associated With Oral Mucositis
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Malignant Neoplasm; Oral Pain; Stomatitis
- Interventions
- Best Practice; Methylene Blue; Methylene Blue; Methylene Blue
- Arms
- Group 1 (lower dose methylene blue, standard of care) · Experimental
- Group 2 (medium dose methylene blue, standard of care) · Experimental
- Group 3 (higher dose methylene blue, standard of care) · Experimental
- Group 4 (standard of care) · Active comparator
- Enrollment
- 69
- Primary outcomes
- Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool
- Sponsor
- M.D. Anderson Cancer Center
- Start
- Feb 28, 2019
- Primary completion
- Feb 3, 2022
- Results posted
- Yes
- Registry record
- NCT03469284 · updated Apr 25, 2023
Publications
linked from the registry- Roldan CJ, Huh B, Song J, Nieto Y, Osei J, Chai T, Nouri K, Koyyalagunta L, Bruera E. Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial. BMC Med. 2022 Nov 3;20(1):377. doi: 10.1186/s12916-022-02579-8. PubMed 36324139